{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:50:45Z","timestamp":1781877045053,"version":"3.54.5"},"reference-count":47,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This systematic review and meta\u2010analysis aimed to evaluate the risk of thromboembolic events and assess the overall safety and effectiveness of avatrombopag in adult patients with immune thrombocytopenia using real\u2010world evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was conducted following the PRISMA 2020 guidelines. Observational studies (2020\u20132024) on adults with primary immune thrombocytopenia treated with avatrombopag were included. Primary outcomes were thromboembolic complications and treatment response; secondary outcomes included time to response, treatment discontinuation, and adverse events. Random\u2010effects meta\u2010analyses were performed to synthesise pooled proportions and rates. Risk of bias was assessed using the ROBINS\u2010Version 2 tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifteen studies were included. The pooled proportion of patients with thromboembolic events was 2.82% (95% confidence interval: 1.61%\u20134.27%), with an incidence rate of 3.29 per 100 patient\u2010years (95% CI: 1.81\u20135.08). Response and complete response were achieved by 80.0% and 92.0% of patients, respectively. The median time to response was 11\u2009days, and the discontinuation rate was 18.9%. Adverse events occurred in 4.1% of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In real\u2010world practice, avatrombopag demonstrated high platelet response rates and a low pooled incidence of thrombotic events. These findings add real\u2010world evidence on avatrombopag outcomes in adult immune thrombocytopenia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.70171","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T10:39:35Z","timestamp":1774089575000},"page":"174-185","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010World Safety and Efficacy of Avatrombopag in Adults with Immune Thrombocytopenia: A Systematic Review and Meta\u2010Analysis"],"prefix":"10.1111","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3148-7037","authenticated-orcid":false,"given":"M. L.","family":"Lozano","sequence":"first","affiliation":[{"name":"Department of Haematology, Morales Meseguer University Hospital, Regional Blood Donation Center University of Murcia, IMIB\u2010Pascual Parrilla, CIBERER  Murcia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8747-078X","authenticated-orcid":false,"given":"D.","family":"Valcarcel","sequence":"additional","affiliation":[{"name":"Department of Haematology Vall d'Hebron Institute of Oncology (VHIO) University Hospital Vall d'Hebron  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103820"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18886"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100039\u20101683416"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102342"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2019.04.016"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2019.1624709"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/20420986231224236"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1531824"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.704093"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.3892\/br.2024.1732"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2020.1745168"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12959\u2010023\u201000509\u2010z"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00829"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2198089"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2023.12092"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010021\u201001752\u20104"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2019.1568659"},{"issue":"1","key":"e_1_2_11_19_1","first-page":"693","article-title":"Pooled Safety Analysis of Avatrombopag (AVA) from Clinical Trials","volume":"4","author":"Birhiray R.","year":"2020","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_11_21_1","unstructured":"Cochrane Bias Methods Group and the Cochrane Non\u2010Randomised Studies Methods Group \u201cThe Risk Of Bias In Non\u2010randomized Studies \u2013 of Interventions VERSION 2: LAUNCH VERSION \u201d2024 accessed May 2025 https:\/\/www.riskofbias.info\/welcome\/robins\u2010i\u2010v2."},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental\u20102019\u2010300117"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i03"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1686"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231179856"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27498"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18081"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000533175"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.24875\/RHT.M24000004"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27080"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19975"},{"key":"e_1_2_11_34_1","doi-asserted-by":"crossref","unstructured":"M. E.Mingot\u2010Castellano M. T.Alvarez\u2010Roman M. L.Lozano et\u00a0al. \u201c714 Use of Avatrombopag in Patients with Immune Thrombocytopenia: Interim Analysis of the Phase 4 Adopt Study [Oral presentation]. Presented at: ASH Annual Meeting & Exposition; Abstract 714 \u201d2024.","DOI":"10.1182\/blood-2024-203491"},{"key":"e_1_2_11_35_1","unstructured":"M. E.Mingot Castellano M. T.Alvarez Rom\u00e1n M. L.Lozano Almela et\u00a0al. \u201cPhase 4 adopt study: interim analysis of efficacy and safety results of avatrombopag treatment in adult patients with immune thrombocytopenia [Poster]. Presented at: EHA2024 (European Hematology Association Annual Meeting); Madrid Spain. Poster P2235 \u201d2024."},{"key":"e_1_2_11_36_1","unstructured":"M.Menor G\u00f3mez J. J.Gil Fernandez P.Villafuerte Guti\u00e9rrez et\u00a0al. \u201cAvatrombopag in immune thrombocytopenia (ITP): a real\u2010life single\u2010centre experience in 20 consecutive patients. Presented at: EHA Library; Abstract PB3314. Abstract released 2024 May 14 \u201d2024."},{"key":"e_1_2_11_37_1","unstructured":"F.Zaja Q. A.Hill F.Glen et\u00a0al. \u201cA European retrospective study to describe real\u2010world outcomes treatment patterns and resource use in patients with primary immune thrombocytopenia (ITP) treated with avatrombopag: interim results. Presented at: EHA Library; Abstract PB3310. Abstract released 2024 May 14 \u201d2024."},{"key":"e_1_2_11_38_1","unstructured":"R.Tomasello L.Garabet H.Pettersen et\u00a0al. \u201cReal\u2010world use effectiveness and safety of romiplostim eltrombopag and avatrombopag in immune thrombocytopenia: data from the Norwegian ITP Registry. Presented at: 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III; 6:00 PM\u20138:00 PM \u201d2023."},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000977236.16342.c2"},{"key":"e_1_2_11_40_1","unstructured":"B.Skopec D.Pulanic andL.Cervinek \u201cReal\u2010World Insights into Avatrombopag's Effectiveness and Safety in Adults with Immune Thrombocytopenia [P\u00f3ster]. Presented at: EHA2024 (European Hematology Association Annual Meeting); P\u00f3ster P2234 \u201d2024."},{"key":"e_1_2_11_41_1","doi-asserted-by":"crossref","unstructured":"M. D.Tarantino S.Kolodziej J.Zhang B.Jamieson andM.Vredenburg \u201c2560 Results of a Prospective Open\u2010Label Phase 4 Study Evaluating the Safety Efficacy and Treatment Satisfaction in Adult Immune Thrombocytopenia (ITP) Subjects after Switching to Avatrombopag From Eltrombopag or Romiplostim [Abstract]. Presented at: ASH Annual Meeting & Exposition \u201d2024 Abstract 2560.","DOI":"10.1182\/blood-2024-205489"},{"key":"e_1_2_11_42_1","doi-asserted-by":"crossref","unstructured":"M. D.Tarantino S.Kolodziej M.Marrone B.Jamieson andM.Vredenburg \u201c2559 Enhanced Patient Satisfaction and Stability of Platelet Counts Following a Switch from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA) in Adult Idiopathic Thrombocytopenic Purpura (ITP): Post\u2010Hoc Analyses from a Prospective Phase 4 Study [Abstract]. Presented at: ASH Annual Meeting & Exposition \u201d2024 Abstract 2559.","DOI":"10.1182\/blood-2024-205466"},{"key":"e_1_2_11_43_1","doi-asserted-by":"crossref","unstructured":"S.Nagalla M. Y.Levy S.Chaturvedi et\u00a0al. \u201cReal\u2010world treatment patterns and outcomes in patients with primary immune thrombocytopenia treated with avatrombopag in the United States: Real\u2010AVA 2.0 interim analysis results. Presented at: 905. Outcomes Research: Non\u2010Malignant Conditions Excluding Hemoglobinopathies: Poster II; 6:00 PM\u20138:00 PM. Abstract presented at Hematology Disease Topics & Pathways \u201d2024.","DOI":"10.1182\/blood-2024-200320"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15573"},{"key":"e_1_2_11_45_1","unstructured":"R.Birhiray Z.Amin K.Aggarwal M.Vredenburg W.Tian andH.Maitland \u201cPooled safety analysis of avatrombopag (AVA) from clinical trials [P\u00f3ster]. EHA Library; Jun 12. Abstract no. 294127; EP1646 \u201d2020."},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2021.1881952"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12206422"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102008\u201007\u2010162503"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70171","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70171","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:53:42Z","timestamp":1781873622000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/ejh.70171"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70171","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"2026-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}